Shares of Gilead Sciences jumped in trading following full approval for Veklury (remdesivir) as a treatment for Covid-19.

Moderna Inc. completed the enrollment of 30,000 participants in a late-stage study testing the company’s experimental coronavirus vaccine, with over a third of the participants from communities of color.

Aptinyx Jumps Following Positive Phase II PTSD Study Results Published: Oct. 20, 2020 By Alex Keown BioSpace   Shares of Aptinyx skyrocketed more than 75% after the company reported its mid-stage experimental treatment for post-traumatic stress disorder demonstrated clinically meaningful and statistically significant results that will set up a pivotal study next year. This morning, […]

The UK government’s Covid-19 Vaccine Taskforce and the contract research company Open Orphan announced a $13 million (£10 million) plan to test investigational vaccines in volunteers who are then intentionally exposed to SARS-CoV-2, the virus that causes Covid-19.

The U.S. health regulator’s criteria for allowing emergency use of a Covid-19 vaccine and plans to monitor its safety after a regulatory go-ahead are among the topics to be discussed at a closely watched meeting.

Moderna Inc. Chief Executive Officer Stéphane Bancel expects interim results from the company’s Covid-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported.

The U.S. Food and Drug Administration granted Roche’s Venclexta (venetoclax) full approval in combination with azacytidine, or decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia in adults 75 years or older.

The U.S. Food and Drug Administration granted full approval of Genentech’s Venclexta (venetoclax) in combination with azacitidine, or decitabine or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Galapagos and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet the study’s primary endpoint in osteoarthritis knee repair.

Pfizer will not seek Emergency Use Authorization (EUA) for the company’s Covid-19 vaccine until the end of November even if the readout from a Phase III study expected during October is positive.